Ấn Độ không quan ngại về tác dụng phụ của vaccine AstraZeneca

Ngày 17/3, quan chức y tế Ấn Độ Vinod Kumar Paul khẳng định rằng nước này không lo ngại về tác dụng phụ tiềm ẩn của vaccine AstraZeneca đang được sử dụng trong chương trình tiêm chủng quốc gia.

w5Up4bucxqDhu7YwVeG6p+G6p+G7iuG7luG6teG6rDzhuq0wI+G7lsOU4buNMsag4buXw6DGoCApOTIoxqDDouG6qVUyxqAyKOG7pDzGoOG6vzrGoOG6rcOa4bu2xqDhu7hjMijGoOG6tSljxqDhu7ZkVcag4bq/VeG7tuG7tjwyI8agw63huqfhuq3huqVVWiMyI+G7tlXDlS8p4bucw5TDleG6tcag4bu2MFXhuqfhuqfhu4rhu5bhurXDuSNV4bu44buWw5R3KMOZ4buDxqDhu5xSL+G7nk/GoMOi4bqpVTLGoOG7tinDqeG7tsag4buDxqDhuq0/xqDhu40yxqDhu5fDoMag4bq+PDIz4bu4xqDhu63huqkxVeG6pcag4bq0VeG6qTDGoCAp4busMijGoEB9MinGoOG6peG7qjIoxqAyZcSD4bu2xqAyw5nhu4PGoCApOTIoxqAwM8agMijhu6Q8xqDhur86xqDhuq3DmuG7tsag4bu4YzIoxqDhurUpY8ag4bqtPDoxxqDDnTLGoOG7tmRVxqDhur9V4bu24bu2PDIjxqDDreG6p+G6reG6pVVaIzIj4bu2VcagQFUyKMagQGXhurHhu7bGoOG6p+G6vcag4bu4YzIoxqDhuq3huqUzMijGoOG7tillw6MyKMag4bqt4bqlezIpxqDhuq08JjHGoOG7tilkMijGoMOi4bqpYeG7tsagKDxVw5PDlS/hurXDlMOV4bq1xqDhu7YwVeG6p+G6p+G7iuG7luG6teG7kzPhu7jhu4Phu5bDlMOVPDEoxqDhu7YwVeG6p+G6p+G7iuG7luG7tjHhuqct4bq1KTPhuq0z4buWxqDhuq084bqtMCPhu4rhu5bhu40yxqDhu5fDoMagICk5MijGoMOi4bqpVTLGoDIo4bukPMag4bq/Osag4bqtw5rhu7bGoOG7uGMyKMag4bq1KWPGoOG7tmRVxqDhur9V4bu24bu2PDIjxqDDreG6p+G6reG6pVVaIzIj4bu2VcagKXsyKcag4bumMinGoOG7nOG7lsag4bqn4bql4bu24buK4buWLy/hu7bDk+G7tFUz4bqtKVUyKSkzVcOT4bq/Mi88MSgv4bu4I+G6pyDhuq0z4bq1LzIj4buB4bqnL+G7ouG7nOG7nOG7nC/hu5xSUuG7uOG7oOG7mlPhu5zhu6JQUeG6reG7ouG7mlRSMOG7nMOT4buBI+G7tOG6teG7lsagVTDhuq3hu4rhu5bhu40yxqDhu5fDoMagICk5MijGoMOi4bqpVTLGoDIo4bukPMag4bq/Osag4bqtw5rhu7bGoOG7uGMyKMag4bq1KWPGoOG7tmRVxqDhur9V4bu24bu2PDIjxqDDreG6p+G6reG6pVVaIzIj4bu2VeG7lsag4bu4VeG6rVUt4bq1KTPhuq0zLTPhuqU8KDwyVTAt4bqn4bql4bu24buK4buWKeG6reG6reG6teG6p00vL+G7tuG7uDI8MSjDk+G6vzwj4bqtMlUx4bq1MOG6qeG6p8OT4bq/Mi/huq1R4bui4buaL+G6qeG6tTAzVeG7uCPhu7gvPOG6v+G6teG7g+G7tjzhur8zL+G7ouG7muG7ouG7nF/hu5rhu55f4bucUi/huq3huq3hu4fhur8yX+G6v1Xhu7bhu7Y8MiNf4bu2M+G6vzzhu7jhu5xUw5Mi4bq1KOG7lsagL8OUxKkyKcagMTwyKcagKTZVxqDhu4x3KOG6qcOhMk3GoMOtdeG6tC/huqzhuqzhu4bhur534buOw5Uv4bq1w5TDleG6tcag4bu2MFXhuqfhuqfhu4rhu5bhurXhu5Mz4bu44buD4buWw5Thu7kyKMag4but4bqpMVXhuqXGoOG6tFXhuqkwxqBAZVXGoOG6pVXGoOG6reG6qeG7gyYyxqDhu7RhxqDhuq3huqUmMsag4bqt4bqlMzIoxqDhu7RhPMag4bu24bumMinGoDHDoOG6rcag4bqnYcagMmXEg+G7tsagMDPGoDIo4bukPMag4bu2w5rhu7bGoOG6rcOa4bu2xqDhu7hjMijGoOG7tmRVxqDhurUpY8ag4bu2ZFXGoMOt4bqn4bqt4bqlVVojMiPhu7ZVxqAwPCYyxqDDouG6qVUyxqDhuq3EgzzGoOG7tinDqTIoxqAp4bqp4buDP+G6rcagIClhPMag4bqtXTIpxqAx4buk4bu2Kcag4buM4bu2Y+G7tsagMcOa4bqpxqBAOTIo4buOT8ag4bqt4bqlMzIoxqAgKTzGoDIpPDrhuqnGoDJlxIPhu7bGoDIpZcag4buTW0/GoOG7mVUyVeG7uFVPxqDDreG6qeG6p+G6reG6pVUwPFVPw5PDk8OTxqDhur/hu7IyxqDhuq08Msag4bu4YjIow5PDlS/hurXDlMOV4bq1xqDhu7YwVeG6p+G6p+G7iuG7luG6teG7kzPhu7jhu4Phu5bDlOG7mcOjxqDDouG6qVUyxqDDguG6qeG7pjLGoDDhu4XGoOG7uGXhurHhu7bGoOG6tSnDnTHGoOG7tilW4bqpxqDDsuG6qcag4buMxqF2w63hu47GoOG7tMOZ4buDxqDhuq03xqDigJzhuq08Msag4bqtZeG6tzIoxqDhu7Yp4buo4bu2xqDhu7Yp4buoMuKAncag4bq/w5kzxqApPDvhuqnGoMOi4bqp4bumxqDhu7ZkVcag4bq/VeG7tuG7tjwyI8agw63huqfhuq3huqVVWiMyI+G7tlXGoOG6reG6pTMyKMag4bq1KTUyKMagMijhurlVxqDhu7Q7MinGoOG7mXjhur7hu6Xhu5Ut4bucVMagw5PGoOG7leG6u8agIDw/Msag4bqs4bqhxqDhu7Ypw6nhu7bGoOG7gsag4bqtP8ag4bqtKT/GoCg8xIM8xqDhu4zhu4DDuXjhu47GoOG6pyrGoOG6p8SDMcag4bu2NMagID/huq3GoDDhuqlZMsag4bu24bqpYTzGoOG7tmIyKMag4bq/Osag4bq/VzLGoEA6xqAyw5nhu4PDk8OVL+G6tcOUw5XhurXGoOG7tjBV4bqn4bqn4buK4buW4bq14buTM+G7uOG7g+G7lsOU4buZYjIoxqAyKMOZ4buDxqDhu5xSL+G7nk/GoOG7tik+MinGoMOi4bqp4buDOjLGoOG6tFUwI+G6p+G6rTwyI8agQMWoxqDhuq08P+G6tcagMilZMsagMDnGoOG6v1Xhu7bhu7Y8MiPGoDIo4bq5Vcag4buZeOG6vuG7peG7lS3hu5xUxqBAWOG6qcag4bqtPCYyT8agQGXhurHhu7bGoOG6tSlWMsag4bq1KWE8xqDhuq0pIzPGoOG7mXjhur7DreG7hsagLcag4bu2KWXDozIoxqDhuq3huqV7MinGoOG6tSlWMsag4bq1KWE8xqDhur9V4bu24bu2PDIjxqDhu7YpM8ag4bu2w5rhu7bGoDJlxIPhu7bGoOG7tjTGoOG6rSnhuqnGoDIpWeG6tcag4bqtKVfhurXGoOG6v8OZxqDhuq3huqXhuqkyKMag4bu0ezIpxqDhu7gzxqDhu4DDuXjGoCAp4bq3PMag4buHZcSDMijDk8OVL+G6tcOUw5XhurXGoOG7tjBV4bqn4bqn4buK4buW4bq14buTM+G7uOG7g+G7lsOU4bqsKSMzxqAyKGXhuq88xqDhurUpw5rhuq3GoDIoOTLGoOG7tsOjxqDDouG6qVUyxqDhu4PGoOG6rT/GoOG7tmRVxqDhurRVMCPhuqfhuq08MiNPxqAwOcag4bq/VeG7tuG7tjwyI8ag4bqt4bqlJjLGoCjDoTHGoOG7nlPDk+G7muG7muG7msagMDw64bqpxqDhur9V4bu24bu2PDIjxqDhu7ZkVcag4bq0ITx6I+G6pS/hu5M8M3fhuqwj4bu2Kcag4bq/w5nGoOG7ouG7oMOT4bua4bua4buaxqAwPDrhuqnGoOG6v1Xhu7Y84bu2MiPGoOG7tmRVxqDDreG6p+G6reG6pVVaIzIj4bu2VcOTw5Uv4bq1w5TDleG6tcag4bu2MFXhuqfhuqfhu4rhu5bhurXhu5Mz4bu44buD4buWw5Thu5XhurvGoCA8PzJPxqDhuq3huqUzMijGoOG6v8OZPMag4bqtKcOaMijGoOG6rcSDPE/GoOG6tFUwI+G6p+G6rTwyI8ag4bqnKsag4bqtPD/hurXGoOG6rWPhu7bGoDIpWTLGoEBl4bqx4bu2xqDhur9V4bu24bu2PDIjxqDhuq0pIzPGoOG7tsOjxqDhu7YpP8ag4buZeOG6vsOt4buGw5PGoOG7mSk+MinGoMOi4bqp4buDOjLGoOG6tFUwI+G6p+G6rTwyI8agQOG7sOG6rcagMWPhu7bGoOG6rTwm4bqpxqDhuqcqxqDhuq08JjHGoOG7tilkMijGoEBl4bqx4bu2xqDhu7YpM8ag4bui4buaxKjGoDIoZeG6rzzGoOG7uFYyT8ag4bq/xIM8xqDhu7bDmuG7tsagQGE8xqDhuq1l4bqxMijGoGXhuqnGoOG6rTwmMsagMMOZxqAyKVYyxqDhur88JjLGoOG7g8ag4bqtP0/GoOG7tDsyKcagMilWMsag4bqtKVkyxqDhur/Dmcag4bqpMijGoOG6rSllxqDhu7bEkTIoxqAyKWXGoDIoZeG6rzzGoOG6reG6pSYyxqBSUMag4bqt4bqp4bqhPMOTw5Uv4bq1w5TDleG6tcag4bu2MFXhuqfhuqfhu4rhu5bhurXhu5Mz4bu44buD4buWw5Thuqzhu6Q8xqDhu60p4bqpxqDhu5Phuq/GoOG6rFbhu4NPxqAyw6M8xqDhu7Y0xqDhu55P4bucxqDhuq3huqU8O+G6qcagMihl4bqvPMag4bq0VTAj4bqn4bqtPDIjxqDhuqc8MinGoOG6p2EyKE/GoEDFqMagKCk8xqAyKVkyxqDhu5zhu6BRw5Phu55QVMag4bu2VcagMik8LjHGoOG6vzzhuqXhuqnhuqfGoOG6psOt4bqk4bqmLeG7mTPhur4t4buixqAoVuG7g8ag4bu0OzIpxqDhu5l44bq+4bul4buVLeG7nFRPxqDhu7RVM8agKMOhMcag4bucw5NRUVLGoOG7tlXGoOG6reG6vcag4bq/MzIow5PGoOG6rOG7pDzGoOG7leG7pjzGoMO6VXpVxqBAxajGoCgpPMagMilZMsagKcOjMsagUFLDk1NU4bucxqDhu7ZVxqDhu7hlw6MyKMag4bqtPjIpT8ag4bqt4bqlMzIoxqBANMagUFLhu6LGoOG7tlXGoOG6reG6vcag4bq/MzIow5PDlS/hurXDlMOV4bq1xqDhu7YwVeG6p+G6p+G7iuG7luG6teG7kzPhu7jhu4Phu5bDlOG6rCkjM8agKDzEgzzGoOG7tinDqeG7tsag4buDxqDhuq0/xqDhurfGoMO6VXpVT8agICkz4bumMijGoFPDk1Dhu5rhu5rGoDIoZeG6rzzGoEDFqMagQGXhurHhu7bGoOG6rTwmMcag4bu2KWQyKMagMcSRPMagQFjhuqnGoOG6rTwmMsag4bu2ZFXGoOG6v1Xhu7bhu7Y8MiPGoOG6puG6teG6qeG6rTI8IMag4bq+xqDhu7ZkVcagdyhVw5PGoOG6rOG7pDzGoCAp4bqpxqDhu5Phuq/GoOG6rFbhu4NPxqDhu7YzMsag4bqnYcagMsOZ4buDxqAww5nGoFDDk+G7muG7muG7msagMihl4bqvPMOTL8OTw5Uv4bq1w5TDleG6tcag4bu2MFXhuqfhuqfhu4rhu5bhurXDreG6qeG6rSkz4bql4buWw5Thu4zhuqzhuqzhu4bhur53L+G6vjwj4bqtMlUxK+G7jsOVL+G6tcOU

Bình luận

Xin vui lòng gõ tiếng Việt có dấu

Tin cùng chuyên mục

Chi phí xung đột Israel - Iran vượt 11 tỷ USD

Chi phí xung đột Israel - Iran vượt 11 tỷ USD

Thế giới
(Baothanhhoa.vn) - Theo thông báo của Bộ Tài chính Israel, chi phí từ xung đột giữa Israel và Iran đang gia tăng nhanh chóng, với ước tính chi phí trực tiếp từ xung đột với Iran kể từ cuối tháng 2/2026 đã lên tới khoảng 35 tỷ shekel (tương đương 11,5 tỷ USD).
Chứng nhận tín nhiệm mạng
Việt Long Phần mềm tòa soạn
hội tụ thông minh